Skip to main content

Research Repository

Advanced Search

All Outputs (98)

Nebivolol as a Potent TRPM8 Channel Blocker: A Drug-Screening Approach through Automated Patch Clamping and Ligand-Based Virtual Screening (2022)
Journal Article
Jahanfar, F., Sadofsky, L., Morice, A., & D’Amico, M. (2022). Nebivolol as a Potent TRPM8 Channel Blocker: A Drug-Screening Approach through Automated Patch Clamping and Ligand-Based Virtual Screening. Membranes, 12(10), Article 954. https://doi.org/10.3390/membranes12100954

Transient Receptor Potential Melastatin 8 (TRPM8) from the melastatin TRP channel subfamily is a non-selective Ca2+-permeable ion channel with multimodal gating which can be activated by low temperatures and cooling compounds, such as menthol and ici... Read More about Nebivolol as a Potent TRPM8 Channel Blocker: A Drug-Screening Approach through Automated Patch Clamping and Ligand-Based Virtual Screening.

Investigating the diagnostic utility of high-resolution oesophageal manometry in patients with refractory respiratory symptoms (2022)
Journal Article
Sykes, D. L., Crooks, M. G., Hart, S. P., Jackson, W., Gallagher, J., & Morice, A. H. (2022). Investigating the diagnostic utility of high-resolution oesophageal manometry in patients with refractory respiratory symptoms. Respiratory medicine, 202, Article 106985. https://doi.org/10.1016/j.rmed.2022.106985

Background: The interaction between the respiratory and gastrointestinal systems, and the role of the latter in the development of respiratory pathology, has been examined with a focus on gastro-oesophageal reflux disease (GORD). However, little data... Read More about Investigating the diagnostic utility of high-resolution oesophageal manometry in patients with refractory respiratory symptoms.

Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups (2022)
Journal Article
Smith, J. A., Birring, S. S., Dicpinigaitis, P. V., McGarvey, L. P., Morice, A. H., Pavord, I. D., …Muccino, D. (2022). Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups. Lung, 200(4), 423-429. https://doi.org/10.1007/s00408-022-00553-y

Introduction: In phase 3 trials (COUGH-1/COUGH-2), gefapixant 45 mg twice daily significantly reduced 24-h cough frequency vs placebo in refractory or unexplained chronic cough (RCC or UCC). Methods: Here, the efficacy of gefapixant 45 mg vs placebo... Read More about Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined Subgroups.

Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study (2022)
Journal Article
Friedrich, C., Francke, K., Gashaw, I., Scheerans, C., Klein, S., Fels, L., …Morice, A. (2022). Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study. Clinical Pharmacokinetics, 61, 1143–1156. https://doi.org/10.1007/s40262-022-01126-1

Background and Objective: There is no licensed treatment for refractory chronic cough; off-label therapies have limited efficacy and can produce adverse effects. Excessive adenosine triphosphate signaling via P2X3 receptors is implicated in refractor... Read More about Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study.

Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough (2022)
Journal Article
Dicpinigaitis, P. V., Birring, S. S., Blaiss, M., McGarvey, L. P., Morice, A. H., Pavord, I. D., …Muccino, D. (2023). Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough. Annals of Allergy, Asthma and Immunology, 130(1), 60-66. https://doi.org/10.1016/j.anai.2022.05.003

Background: The current characterization of patients with refractory or unexplained chronic cough (RCC and UCC, respectively) primarily stems from relatively small clinical studies. Objective: To report the baseline medical history and clinical chara... Read More about Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic cough.

Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS) (2022)
Journal Article
Cotton, S., Devereux, G., Abbas, H., Briggs, A., Campbell, K., Chaudhuri, R., …Lipworth, B. J. (2022). Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS). Trials, 23(1), Article 307. https://doi.org/10.1186/s13063-022-06226-8

Background: Chronic obstructive pulmonary disease (COPD) is associated with significant morbidity, mortality and healthcare costs. Beta blockers are well-established drugs widely used to treat cardiovascular conditions. Observational studies consiste... Read More about Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS).

Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials (2022)
Journal Article
McGarvey, L. P., Birring, S. S., Morice, A. H., Dicpinigaitis, P. V., Pavord, I. D., Schelfhout, J., …Smith, J. A. (2022). Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials. Lancet, 399(10328), 909-923. https://doi.org/10.1016/S0140-6736%2821%2902348-5

Background: Gefapixant is an oral P2X3 receptor antagonist that has previously shown efficacy and safety in refractory chronic cough and unexplained chronic cough. We therefore aim to confirm the efficacy and safety of gefapixant in participants with... Read More about Efficacy and safety of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough and unexplained chronic cough (COUGH-1 and COUGH-2): results from two double-blind, randomised, parallel-group, placebo-controlled, phase 3 trials.

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough (2022)
Journal Article
McGarvey, L., Smith, J. A., Morice, A., Birring, S. S., Chung, K. F., Dicpinigaitis, P. V., …Gomez, J. C. (2022). A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough. Lung, https://doi.org/10.1007/s00408-022-00592-5

Introduction: To determine the optimal dose of sivopixant, a highly selective P2X3 receptor antagonist, for refractory or unexplained chronic cough (RCC/UCC). Methods: In this phase 2b, randomized, double-blind, placebo-controlled, parallel-group, mu... Read More about A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough.

Adaptive study design to assess effect of TRPV4 inhibition in patients with chronic cough (2021)
Journal Article
Ludbrook, V. J., Hanrott, K. E., Kreindler, J. L., Marks-Konczalik, J. E., Bird, N. P., Hewens, D. A., …Smith, J. (2021). Adaptive study design to assess effect of TRPV4 inhibition in patients with chronic cough. ERJ Open Research, 7(3), Article 00269-2021. https://doi.org/10.1183/23120541.00269-2021

Objective Airway sensory nerves involved in the cough reflex are activated by adenosine triphosphate (ATP) agonism of P2X purinoceptor 3 (P2X3) receptors. Transient receptor potential vanilloid 4 (TRPV4) channel activation causes ATP release from air... Read More about Adaptive study design to assess effect of TRPV4 inhibition in patients with chronic cough.

Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: A randomised, placebo-controlled, crossover phase 2a study (2021)
Journal Article
Morice, A., Smith, J. A., McGarvey, L., Birring, S. S., Parker, S. M., Turner, A., …Friedrich, C. (2021). Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: A randomised, placebo-controlled, crossover phase 2a study. European respiratory journal, 58(5), Article 2004240. https://doi.org/10.1183/13993003.04240-2020

Background. ATP acting via P2X3 receptors is an important mediator of refractory chronic cough (RCC). This phase 2a double-blinded crossover study assessed the safety, tolerability and efficacy of eliapixant (BAY 1817080), a selective P2X3 receptor a... Read More about Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: A randomised, placebo-controlled, crossover phase 2a study.

Domiciliary Cough Monitoring for the Prediction of COPD Exacerbations (2021)
Journal Article
Crooks, M. G., den Brinker, A. C., Thackray-Nocera, S., van Dinther, R., Wright, C. E., & Morice, A. H. (2021). Domiciliary Cough Monitoring for the Prediction of COPD Exacerbations. Lung, 199(2), 131-137. https://doi.org/10.1007/s00408-021-00435-9

Introduction: Acute exacerbations of COPD (AE-COPD) are a leading cause of health service utilisation and are associated with morbidity and mortality. Identifying the prodrome of AE-COPD by monitoring symptoms and physiological parameters (telemonito... Read More about Domiciliary Cough Monitoring for the Prediction of COPD Exacerbations.

Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant (2021)
Journal Article
Morice, A. H., Birring, S. S., Smith, J. A., McGarvey, L. P., Schelfhout, J., Martin Nguyen, A., …Sher, M. R. (2021). Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant. Lung, 199(2), 121-129. https://doi.org/10.1007/s00408-021-00437-7

Purpose: This analysis assesses clinical characteristics of patients with refractory chronic cough (RCC) or unexplained chronic cough (UCC) enrolled in a phase 2 study to better understand this patient population. Methods: Patients with RCC/UCC lasti... Read More about Characterization of Patients With Refractory or Unexplained Chronic Cough Participating in a Phase 2 Clinical Trial of the P2X3-Receptor Antagonist Gefapixant.

Post-COVID-19 Symptom Burden: What is Long-COVID and How Should We Manage It? (2021)
Journal Article
Sykes, D. L., Holdsworth, L., Jawad, N., Gunasekera, P., Morice, A. H., & Crooks, M. G. (2021). Post-COVID-19 Symptom Burden: What is Long-COVID and How Should We Manage It?. Lung, 199(2), 113-119. https://doi.org/10.1007/s00408-021-00423-z

© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature. The enduring impact of COVID-19 on patients has been examined in recent studies, leading to the description of Long-COVID. We report the l... Read More about Post-COVID-19 Symptom Burden: What is Long-COVID and How Should We Manage It?.

Rhinovirus-16 increases ATP release in A549 cells without concomitant increase in production (2020)
Journal Article
Atkinson, S. K., Morice, A. H., & Sadofsky, L. R. (2020). Rhinovirus-16 increases ATP release in A549 cells without concomitant increase in production. ERJ Open Research, 6(4), Article 00159-2020. https://doi.org/10.1183/23120541.00159-2020

Human rhinovirus (RV) is the most common cause of upper respiratory tract infection (URTI) and chronic airway disease exacerbation. Cough is present in 50–80% of URTI cases, accompanied by heightened airway hypersensitivity, yet no effective treatmen... Read More about Rhinovirus-16 increases ATP release in A549 cells without concomitant increase in production.

Azithromycin for sarcoidosis cough: an open label exploratory clinical trial (2020)
Journal Article
Fraser, S. D., Thackray-Nocera, S., Shepherd, M., Flockton, R., Wright, C., Sheedy, W., …Hart, S. P. (2020). Azithromycin for sarcoidosis cough: an open label exploratory clinical trial. ERJ Open Research, 6(4), Article 00534. https://doi.org/10.1183/23120541.00534-2020

Background: Chronic cough is a distressing symptom for many people with pulmonary sarcoidosis. Continuous treatment with a macrolide antibiotic may improve cough. We aimed to assess the potential efficacy of azithromycin in patients with sarcoidosis... Read More about Azithromycin for sarcoidosis cough: an open label exploratory clinical trial.

An audit of COPD: Diagnosis and management in general practice (2020)
Journal Article
Hamad, G., Rigby, A., & Morice, A. H. (2020). An audit of COPD: Diagnosis and management in general practice. ERJ Open Research, 6(4), Article 00330-2020. https://doi.org/10.1183/23120541.00330-2020

Introduction: COPD is a spectrum of disorders primarily caused by smoking and characterised by progressive, not fully reversible airflow obstruction with a forced expiratory volume in 1 s (FEV1)/forced vital capacity (FVC) ratio

Design and rationale of two phase 3 randomised controlled trials (Cough-1 and cough-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough (2020)
Journal Article
Muccino, D. R., Morice, A. H., Birring, S. S., Dicpinigaitis, P. V., Pavord, I. D., Assaid, C., …Smith, J. A. (2020). Design and rationale of two phase 3 randomised controlled trials (Cough-1 and cough-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough. ERJ Open Research, 6(4), Article 00284-2020. https://doi.org/10.1183/23120541.00284-2020

Background: We present study designs, dose selection and preliminary patient characteristics from two phase 3 clinical trials of gefapixant, a P2X3 receptor antagonist, in refractory chronic cough (RCC) or unexplained chronic cough (UCC). Methods: CO... Read More about Design and rationale of two phase 3 randomised controlled trials (Cough-1 and cough-2) of gefapixant, a P2X3 receptor antagonist, in refractory or unexplained chronic cough.

Alert system design based on experimental findings from long-term unobtrusive monitoring in COPD (2020)
Journal Article
den Brinker, A. C., van Dinther, R., Crooks, M. G., Thackray-Nocera, S., & Morice, A. H. (2021). Alert system design based on experimental findings from long-term unobtrusive monitoring in COPD. Biomedical Signal Processing and Control, 63, Article 102205. https://doi.org/10.1016/j.bspc.2020.102205

An observational study using a cough count monitor was executed in the home of 30 patients with Chronic Obstructive Pulmonary Disease (COPD). The monitoring system was unobtrusive, allowing long-term monitoring. This paper illustrates the cough count... Read More about Alert system design based on experimental findings from long-term unobtrusive monitoring in COPD.

Objective Assessment of Cough: An Early Marker of Response to Biological Therapies in Asthma? (2020)
Journal Article
Faruqi, S., Sykes, D. L., Crooks, M. G., Brindle, K., Thompson, J., & Morice, A. H. (2020). Objective Assessment of Cough: An Early Marker of Response to Biological Therapies in Asthma?. Lung, 198(5), 767-770. https://doi.org/10.1007/s00408-020-00391-w

© 2020, Springer Science+Business Media, LLC, part of Springer Nature. Cough is an important symptom of asthma. The objective assessment of chronic cough has been enhanced by the development of ambulatory cough monitoring systems. Mepolizumab has bee... Read More about Objective Assessment of Cough: An Early Marker of Response to Biological Therapies in Asthma?.